- David Haussler, Ph.D., Delivers a Lecture on Cancer Genomics and the Significance of TCGA(14:04)
In this lecture, Dr. David Haussler provides a historical overview of the field of genomics leading up to TCGA, including the Cancer Genomics Hub at the University of California, Santa Cruz, and the TCGA Pan-Cancer initiative.
- Neil Hayes, M.D., M.P.H., Talks about What TCGA Means for the Future of Personalized Care(3:18)
Dr. Neil Hayes speaks about the intersection of scientific research and clinical medicine, and the implications of TCGA for the future of personalized cancer care.
- Neil Hayes, M.D., M.P.H., Summarizes Key Findings from the TCGA Study of Lung Cancer(7:12)
Dr. Neil Hayes provides a summary of important findings from the TCGA marker paper mapping the genetic basis of lung squamous cell carcinoma.
- Vesteinn Thorsson, Ph.D., Reviews Key Findings from the TCGA Study on Colorectal Cancer(4:03)
Dr. Vesteinn Thorsson highlights important findings from the TCGA comprehensive analysis of colorectal cancer.
- David Haussler, Ph.D., and Christopher Benz, M.D., Describe How Genomics Research can Advance Personalized Cancer Care(4:11)
Dr. David Haussler and Dr. Christopher Benz explain how integration of large-scale genomics data in cancer genomics research can accelerate the path to personalized care.
- Peter Laird, Ph.D., Talks about the Transformative Role of Epigenetics in Cancer Research(4:59)
Director of the University of Southern California’s Epigenome Center Dr. Peter Laird highlights important advances in the field of epigenetics and how it is transforming cancer research.
- Gordon Mills, M.D., Ph.D., Discusses Unexpected Therapy Responses in Some Cancer Patients(1:02)
Dr. Gordon Mills provides three examples of therapies that have demonstrated unexpected benefits for some cancer patients.
- Gordon Mills, M.D., Ph.D., Provides an Overview of the Field of Targeted Therapeutics(1:28)
Dr. Gordon Mills discusses early successful targeted cancer therapies like Gleevec and the next steps for creating more effective targeted therapies in the future.
- Timothy Ley, M.D., Advocates for Personalized Medicine in the Treatment of AML(2:41)
Oncologist Dr. Timothy Ley talks about how repurposing of existing drugs based on better understanding of the genetic basis of acute myeloid leukemia (AML) can help patients receive personalized care.
- Paul Spellman, Ph.D., Discusses New Study on Genetics of Ovarian Cancer(2:34)
Computational scientist Dr. Paul Spellman discusses the results of a new TCGA study to genomically characterize ovarian cancer.
- Paul Spellman, Ph.D., Talks about TCGA at AACR 2011(8:50)
Dr. Paul Spellman discusses how TCGA could help advance the treatment of cancer.
- Lynda Chin, M.D., Highlights Important Advances in Cancer Genomics Research, including TCGA, at AACR 2011(6:26)
At the 2011 AACR meeting, Dr. Lynda Chin talks about recent advances in cancer genomics, including the wealth of information that has come from TCGA.
- Charles Perou, Ph.D., Describes the Power of Next-Generation Sequencing Technology in Genomics Research at AACR 2010(5:05)
At the 2010 AACR meeting, Dr. Charles Perou explains how next-generation sequencing technology is transforming cancer genomics research.
- Julie Gastier-Foster, Ph.D., Explains Nationwide Children Hospital’s Role in TCGA(1:48)
Dr. Julie Gastier-Foster discusses Nationwide Children's role as a Biospecimen Core Resource for TCGA.
- Julie Gastier-Foster, Ph.D., Discusses Tissue Collection for TCGA(1:08)
Dr. Julie Gastier-Foster describes the goal of TCGA.
- Julie Gastier-Foster, Ph.D., Anticipates the Future of Personalized Medicine Informed by Findings from TCGA(1:49)
Dr. Julie Gastier-Foster discusses the role TCGA will play in advancing personalized medicine.
- Neil Hayes, M.D., M.P.H., Discusses Personalized Medicine and Lung Cancer Research(5:59)
Dr. Neil Hayes talks about the transition to personalized medicine in lung cancer treatment, new biomarkers, and clinical trials for new targeted therapeutics in lung cancer.
- Cancer Bulletin Profile: In Their Own Words: Raju Kucherlapati, Ph.D.(2:15)
Dr. Raju Kucherlapati, the Paul C. Cabot Professor of Genetics at Harvard Medical School, speaks about cancer genetics and genomics.
- Neil Hayes, M.D., M.P.H., Explains TCGA Findings on Subtypes of Glioblastoma(3:53)
Dr. Neil Hayes reviews TCGA’s finding that glioblastoma comprises four distinct molecular subtypes.
- Stephen Baylin, M.D., Explains Epigenetics(1:14)
Cancer research leader Dr. Stephen Baylin discusses how "things go wrong in cancer" and the role of epigenetics in cancer.
- Stephen Baylin, M.D., Discusses Clinical Implications of TCGA Findings On Glioblastoma(2:51)
Dr. Stephen Baylin discusses the potential clinical implications from decoding the genome of brain cancer, the first cancer type studied by TCGA.
- Stephen Baylin, M.D., Explains the Difference Between Genetics and Epigenetics(1:42)
Dr. Stephen Baylin at the Johns Hopkins Kimmel Cancer Center discusses how alterations in DNA are deciphered by TCGA to decode the brain cancer genome.
- Stephen Baylin, M.D., Explains Why GBM was the First Cancer Type Studied by TCGA(0:42)
Stephen Baylin, M.D. discusses why glioblastoma multiforme (GBM), a deadly brain tumor in adults, was the first cancer chosen for study by TCGA.
More Videos >